Overview

Cannabidiol Oral Solution for the Treatment of Subjects With Prader-Willi Syndrome

Status:
Terminated
Trial end date:
2019-06-10
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the efficacy of Cannabidiol Oral Solution on hyperphagia-related behavior in subjects with Prader-Willi Syndrome (PWS). The secondary objectives of this study are to assess the efficacy, safety and tolerability, impact on quality of life, and impact on physical activity of Cannabidiol Oral Solution in subjects with PWS.
Phase:
Phase 2
Details
Lead Sponsor:
Benuvia Therapeutics Inc.
INSYS Therapeutics Inc
Treatments:
Cannabidiol
Pharmaceutical Solutions